Recombinant Rhesus CD137 Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0677
Recombinant Rhesus CD137 Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0677
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | Fc |
Host Species | Rhesus |
Accession | NP_001253057.1 |
Background | CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor-associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.Immune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsCo-stimulatory Immune Checkpoint Targets ImmunotherapyCancer ImmunotherapyTargeted Therapy |
Description | A DNA sequence encoding the rhesus TNFRSF9 (NP_001253057.1) (Met1-Gln186) was expressed with the Fc region of human IgG1 at the C-terminus. |
Source | HEK293 |
Predicted N Terminal | Leu 24 |
AA Sequence | Met1-Gln186 |
Molecular Weight | The recombinant rhesus TNFRSF9 consists of 401 a.a. and predicts a molecular mass of 44 kDa. |
Purity | >95% as determined by SDS-PAGE. |
Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
Bioactivity | 1.Measured by its binding ability in a functional ELISA. 2.Immobilized rhesus TNFRSF9-Fc at 10ug/mL (100uL/well) can bind biotinylated human TNFSF9, the EC50 of biotinylated human TNFSF9 is 20-100ng/mL. |
Formulation | Lyophilized from sterile PBS, pH 7.4.. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |